Top-Rated StocksTop-RatedPositive News SentimentPositive NewsNASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $63.69 +0.51 (+0.81%) Closing price 03:59 PM EasternExtended Trading$63.37 -0.32 (-0.50%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Bright Minds Biosciences Stock (NASDAQ:DRUG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DRUG alerts:Sign Up Key Stats Today's Range$62.83▼$63.9050-Day Range$63.18▼$84.7452-Week Range$44.25▼$123.75Volume32,102 shsAverage Volume215,854 shsMarket Capitalization$619.69 millionP/E RatioN/ADividend YieldN/APrice Target$143.83Consensus RatingBuy Company Overview Bright Minds Biosciences Inc. is a biotechnology company focused on developing next-generation therapies for neuropsychiatric and neurological disorders. The company’s research centers on selective serotonin receptor agonists designed to address conditions such as treatment-resistant depression, substance use disorders and other disorders involving disrupted brain signaling. Bright Minds’ lead program, BMB-101, is an orally administered, selective 5-HT2C receptor agonist being developed as a potential treatment for conditions including substance use disorder and related neuropsychiatric indications. The company’s drug-development approach is intended to preserve therapeutic effects while reducing some of the adverse effects and limitations associated with less selective psychedelic or serotonergic compounds. Bright Minds Biosciences is based in Vancouver, British Columbia, and conducts biotechnology research and clinical development activities through operations in North America. Its shares trade on the Nasdaq Capital Market under the symbol “DRUG” and on the Canadian Securities Exchange under the same symbol.AI Generated. May Contain Errors. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 367th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingBright Minds Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialBright Minds Biosciences has a consensus price target of $143.83, representing about 125.8% upside from its current price of $63.69.Amount of Analyst CoverageBright Minds Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($2.93) to ($6.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -30.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -30.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 7.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.01% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 7.06.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 0.41%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentBright Minds Biosciences has a news sentiment score of 1.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bright Minds Biosciences this week, compared to 3 articles on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRUG Stock News HeadlinesBright Minds Biosciences to Present at Upcoming ConferencesSeptember 4, 2026 | globenewswire.comBright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal TrialsAugust 10, 2026 | seekingalpha.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 14 at 1:00 AM | Golden Portfolio (Ad)Vistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comBright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceMay 26, 2026 | globenewswire.comWhy a $5 Million New Position Signals Confidence in This Epilepsy Drug PipelineMay 21, 2026 | finance.yahoo.comJefferies initiates coverage of Bright Minds Biosciences (DRUG) with buy recommendationApril 14, 2026 | msn.comWhat Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?March 25, 2026 | insidermonkey.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $78.04 at the beginning of the year. Since then, DRUG shares have decreased by 18.4% and is now trading at $63.6890. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) issued its earnings results on Monday, August, 17th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $1.05. When did Bright Minds Biosciences' stock split? Shares of Bright Minds Biosciences reverse split on the morning of Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are Bright Minds Biosciences' major shareholders? Top institutional shareholders of Bright Minds Biosciences include Braidwell LP (4.97%), Bank of New York Mellon Corp (0.15%), California State Teachers Retirement System (0.07%) and Engineers Gate Manager LP (0.06%). View institutional ownership trends. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), SoFi Technologies (SOFI). Company Calendar Last Earnings8/17/2026Today9/14/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DRUG's financial health is in the Green zone, according to TradeSmith. DRUG has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployees25Year Founded2019Price Target and Rating Average Price Target for Bright Minds Biosciences$143.83 High Price Target$220.00 Low Price Target$80.00 Potential Upside/Downside+125.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-12.46% Return on Assets-12.30% Debt Debt-to-Equity RatioN/A Current Ratio122.00 Quick Ratio122.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book7.65Miscellaneous Outstanding Shares9,730,000Free Float5,580,000Market Cap$619.69 million OptionableNot Optionable Beta-5.36 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:DRUG) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat is Elon Building in Texas?Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...InvestorPlace | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
